Skip to content

Study · Randomized controlled trial · n = 168 · 2024

3 results

Teduglutide improves liver chemistries in short bowel syndrome-associated intestinal failure: Post hoc analysis.

Micic D, Robinson I, Kidd T, Terreri B, Raphael BP

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition16 Mar 2024Cited by 6 (Europe PMC)

PMID38491966 (opens in a new tab)DOI10.1002/ncp.11139 (opens in a new tab)PepBankPUB-38491966
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

BackgroundChronic hepatic complications are common in patients with short bowel syndrome-associated intestinal failure (SBS-IF). Teduglutide, a glucagon-like peptide-2 analogue, demonstrated efficacy in reducing parenteral nutrition and/or intravenous fluid dependence among patients with SBS-IF in phase 3 clinical studies.MethodsThis was a post hoc analysis of pooled data from two separate randomized, double-blind, placebo-controlled, multinational phase 3 clinical studies. Adult patients with SBS-IF with parenteral nutrition and/or intravenous fluid dependence without liver disease at baseline were randomized to treatment with the glucagon-like peptide-2 analogue teduglutide (0.05 or 0.10 mg/kg/day) or placebo subcutaneously once daily for 24 weeks. Mixed-effects models assessed the baseline predictors of change in liver chemistries.ResultsBetween baseline and week 24, teduglutide treatment (n = 109) was associated with least squares mean reductions in aspartate aminotransferase (-7.51 IU/L; P = 0.014), alanine aminotransferase (-12.15 IU/L; P = 0.002), and bilirubin (-5.03 µmol/L [-0.057 mg/dl]; P < 0.001) compared with that of the placebo (n = 59). These values were independent of reductions in parenteral nutrition and/or intravenous fluid dependence.ConclusionTeduglutide treatment was associated with reductions in liver chemistries by week 24, which is beneficial for patients with SBS-IF beyond improvements in parenteral nutrition and/or intravenous fluid dependence. Future studies should examine how long-term teduglutide might mitigate the risk of liver disease in patients with SBS-IF.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with SBS-IF, teduglutide reduced AST by a least squares mean 7.51 IU/L versus placebo at week 24.

    In plain wordsIn adults with SBS-IF, teduglutide reduced AST more than placebo at week 24.

    Peptide
    Teduglutide
    Outcome
    DecreaseAspartate aminotransferase
    Study

    n = 168

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.05 or 0.10 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    AST difference
    −7.51 IU/L
    reported result

    Source sentences

    Summary
    Between baseline and week 24, teduglutide treatment (n = 109) was associated with least squares mean reductions in aspartate aminotransferase (-7.51 IU/L; P = 0.014), alanine aminotransferase (-12.15 IU/L; P = 0.002), and bilirubin (-5.03 µmol/L [-0.057 mg/dl]; P < 0.001) compared with that of the placebo (n = 59).
    3 context sentences
    Summary · context
    These values were independent of reductions in parenteral nutrition and/or intravenous fluid dependence.
    Summary · context
    This was a post hoc analysis of pooled data from two separate randomized, double-blind, placebo-controlled, multinational phase 3 clinical studies.
    Summary · context
    Adult patients with SBS-IF with parenteral nutrition and/or intravenous fluid dependence without liver disease at baseline
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with SBS-IF, teduglutide reduced ALT by a least squares mean 12.15 IU/L versus placebo at week 24.

    In plain wordsIn adults with SBS-IF, teduglutide reduced ALT more than placebo at week 24.

    Peptide
    Teduglutide
    Outcome
    DecreaseAlanine aminotransferase
    Study

    n = 168

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.05 or 0.10 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    ALT difference
    −12.15 IU/L
    reported result

    Source sentences

    Summary
    Between baseline and week 24, teduglutide treatment (n = 109) was associated with least squares mean reductions in aspartate aminotransferase (-7.51 IU/L; P = 0.014), alanine aminotransferase (-12.15 IU/L; P = 0.002), and bilirubin (-5.03 µmol/L [-0.057 mg/dl]; P < 0.001) compared with that of the placebo (n = 59).
    3 context sentences
    Summary · context
    These values were independent of reductions in parenteral nutrition and/or intravenous fluid dependence.
    Summary · context
    This was a post hoc analysis of pooled data from two separate randomized, double-blind, placebo-controlled, multinational phase 3 clinical studies.
    Summary · context
    Adult patients with SBS-IF with parenteral nutrition and/or intravenous fluid dependence without liver disease at baseline
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with SBS-IF, teduglutide reduced bilirubin by 5.03 µmol/L versus placebo at week 24.

    In plain wordsIn adults with SBS-IF, teduglutide reduced bilirubin more than placebo at week 24.

    Peptide
    Teduglutide
    Outcome
    DecreaseBilirubin
    Study

    n = 168

    Comparator
    Placebo
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    0.05 or 0.10 mg/kg/day · subcutaneous · 24 weeksAs given in this study (human).

    Measurements

    Bilirubin difference
    −5.03 µmol/L
    reported result
    Bilirubin difference
    −0.057 mg/dl
    reported result

    Source sentences

    Summary
    Between baseline and week 24, teduglutide treatment (n = 109) was associated with least squares mean reductions in aspartate aminotransferase (-7.51 IU/L; P = 0.014), alanine aminotransferase (-12.15 IU/L; P = 0.002), and bilirubin (-5.03 µmol/L [-0.057 mg/dl]; P < 0.001) compared with that of the placebo (n = 59).
    3 context sentences
    Summary · context
    These values were independent of reductions in parenteral nutrition and/or intravenous fluid dependence.
    Summary · context
    This was a post hoc analysis of pooled data from two separate randomized, double-blind, placebo-controlled, multinational phase 3 clinical studies.
    Summary · context
    Adult patients with SBS-IF with parenteral nutrition and/or intravenous fluid dependence without liver disease at baseline

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.